Items where Subject is "Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > ONCOLOGY AND CARCINOGENESIS (111200) > Molecular Targets (111207)"
|Up a level|
- Subjects classification (39339)
- Australian and New Zealand Standard Research Classification (39339)
Group by: Authors/Creators | Item Type
Number of items at this level: 13.
Byron, Sara A., Gartside, Michael, Powell, Matthew A., Wellens, Candice L., Gao, Feng, Mutch, David G., et al. (2012) FGFR2 point mutations in 466 Endometrioid Endometrial Tumors : relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and Clinicopathological features. PLoS ONE, 7(2), e30801-e30801.
Byron, Sara A., Loch, David, & Pollock, Pamela M. (2012) Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells. International Journal of Gynecological Cancer, 22(9), pp. 1517-1526.
Byron, Sara A., Loch, David C., Wellens, Candice L., Wortmann, Andreas, Wu, Jiayi, Wang, John, et al. (2012) Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. BMC Molecular Cancer, 11(75).
Chopin, L. K., Seim, I., Walpole, C. M., & Herington, A. C. (2012) The Ghrelin axis : does it have an appetite for cancer progression? Endocrine Reviews, 33(6), pp. 849-891.
Dong, Ying, Batra, Jyotsna, Anand, Kamal, Bapat, Sharmila, & Clements, Judith A. (2014) Transforming the future of treatment for ovarian cancer. Clinical & Experimental Pharmacology, 4(3), p. 1000157.
Dutton-Regester, Ken & Hayward, Nicholas K. (2012) Whole genome and exome sequencing of melanoma. Advances in Pharmacology, 65, pp. 399-435.
Dutton-Regester, Ken, Irwin, Darryl, Hunt, Priscilla, Aoude, Lauren G., Tembe, Varsha, Pupo, Gulietta M., et al. (2012) A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Molecular Cancer Therapeutics, 11(4), pp. 888-897.
Jingjing, You, Cozzi, Paul, Fitzgerald , Anna, Walsh, Bradley, Russell, Pamela J., Willcox, Mark, et al. (2012) Prostate cancer biomarkers and the emerging proteomic techniques used in biomarker research. In Watanabe, Hiroto S. (Ed.) Horizons in Cancer Research : Volume 47. Nova Science Publishers Inc, New York, pp. 1-36.
Krauthammer, Michael, Kong, Yong, Ha, Byung Hak, Evans, Perry, Bacchiocchi, Antonella, McCusker, James P, et al. (2012) Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nature Genetics, 44(9), pp. 1006-1014.
Lisle, Jessica E., Mertens-Walker, Inga, Rutkowski, Raphael, Herington, Adrian C., & Stephenson, Sally-Anne (2013) Eph receptors and their ligands : promising molecular biomarkers and therapeutic targets in prostate cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1835(2), pp. 243-257.
Loch, David & Pollock, Pamela M. (2012) Lineage-specific biomarkers predict response to FGFR inhibition. Cancer Discovery, 2, pp. 1081-1083.
Moore, Nicole L., Buchanan, Grant, Harris, Jonathan M., Selth, Luke A., Bianco-Miotto, Tina, Hanson, Adrienne R., et al. (2012) An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocrine Related Cancer, 19(4), pp. 599-613.
Rutowski, Raphael, Mertens-Walker, Inga, Lisle, Jessica E, Herington, Adrian C., & Stephenson, Sally-Anne (2012) Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand. International Journal of Cancer, 131(5), E614-E624.